Novo Nordisk
NVO
#100
Rank
HK$1.534 T
Marketcap
HK$346.20
Share price
-1.71%
Change (1 day)
-37.30%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): HK$33.58

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is HK$33.65. In 2025 the company made an earnings per share (EPS) of HK$27.82 an increase over its 2024 EPS that were of HK$25.64.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$33.5820.73%
2025HK$27.828.48%
2024HK$25.64
2016HK$8.74

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$10.26-69.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$221.13 557.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$20.05-40.41%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
HK$27.89-17.12%๐Ÿ‡บ๐Ÿ‡ธ USA